Orange Book product · Generic (ANDA)
CASPOFUNGIN ACETATE
CASPOFUNGIN ACETATE
At a glance
Sep 29, 2017
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 29, 2017
8 yr 10 mo ago
Today
Pharmaceutical detail
Active ingredient
CASPOFUNGIN ACETATE
Strength
50MG/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
TE code
AP
Application
ANDA 207092
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
Yes
Active-ingredient family
View full familyGeneric (ANDA) of CASPOFUNGIN ACETATE
- 2016CASPOFUNGIN ACETATEBrand (NDA)
NDA 206110 · FRESENIUS KABI USA
- 2001CANCIDASBrand (NDA)
NDA 021227 · MERCK
- 2025CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 216506 · HANGZHOU ZHONGMEI
- 2021CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 211263 · AREVA PHARMS
- 2018CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 209489 · CIPLA
- 2018CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 205923 · XELLIA PHARMS APS
- 2018CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 200833 · HENGRUI PHARMA
- 2017CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 207650 · PHARMOBEDIENT
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
